Abstract
Objective: Animal studies have demonstrated that monoclonal antibodies like guselkumab (GUS) cross the placenta. Although pregnant women and women who intend to become pregnant were excluded from participation in GUS clinical trials, some female patients still became pregnant during the study period and discontinued GUS. Here, we report these pregnancy experiences.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
